Veterinary Antibiotics Market Share, Size, Trends, Industry Analysis Report: By Animal Type (Pigs, Cattle, Sheep & Goats, Poultry, and Others), Drug Class, Dosage Form, and Region (North America, Europe, Asia Pacific, and Rest of World) – Market Forecast, 2025–2034
The global veterinary antibiotics market size is expected to reach USD 6.43 billion by 2034, according to a new study by Polaris Market Research. The report “Veterinary Antibiotics Market Share, Size, Trends, Industry Analysis Report: By Animal Type (Pigs, Cattle, Sheep & Goats, Poultry, and Others), Drug Class, Dosage Form, and Region (North America, Europe, Asia Pacific, and Rest of World) – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Veterinary antibiotics are medications specifically designed for treating bacterial infections in animals. The antibiotics eliminate harmful bacteria or inhibit their growth, thus assisting in the animal's recovery.
There is a growing emphasis on animal-specific antibiotics and ionophores, driven by initiatives from major companies and the introduction of new products. The incidence of livestock diseases is on the rise, leading key players to actively release new antibiotics to meet demand, especially as older antibiotics have been linked to resistance.
The veterinary antibiotics market is expected to grow during the forecast period due to increased awareness of zoonotic diseases, rising animal disease outbreaks, and higher demand for animal-derived food products. Additionally, stringent disease prevention regulations, a growing animal population, increased pet adoption, and the expanding pet health insurance market are driving the market growth.
The increasing adoption of companion animals is propelling the demand for veterinary services and products, including antibiotics. As more people bring pets into their homes, the need for healthcare, preventive measures, and treatments for these animals continues to increase globally.
According to the central disease control report in July 2024, prevention of Zoonotic diseases, which are transmissible between animals and humans, requires a One Health approach for effective management. Notably, 60% of human infectious diseases originate from animals, including pathogens such as HIV and rabies. Additionally, most emerging infectious diseases and 80% of bioterrorism-related diseases, such as anthrax, are zoonotic. The increasing incidence of such diseases among animals boosts the veterinary antibiotics market expansion.
Veterinary Antibiotics Report Highlights
By animal type, the cattle segment dominated the veterinary antibiotics market in 2024 due to the rising consumption of beef and dairy products that necessitate enhanced animal health management.
Based on drug class, in 2024, the tetracyclines segment dominated the market due to their therapeutic applications. These antibiotics are widely used as first-line treatments for food-producing animals and are also frequently administered to companion animals, including dogs, cats, and horses. Tetracycline-based medications such as Achromycin, Sumycin, Medicycline, and Tetracyn are specifically used in veterinary medicine to address bacterial infections and inflammatory skin conditions in animals.
The European veterinary market is expected to grow in the coming years due to the high expenditure on pet care, encompassing food, healthcare, and grooming. Furthermore, technological advancements such as smart pet devices are contributing to the market growth. Shifting consumer preferences, particularly the increasing demand for dietary and vegan pet food, also support the market growth.
A few global key market players are Merck & Co., Inc.; Ceva Santé Animale; Vetoquinol; Zoetis Services LLC; Boehringer Ingelheim International GmbH; Dechra Pharmaceuticals PLC; Elanco Animal Health Incorporated; Virbac S.A.; Calier, Bimeda, Inc.; Prodivet Pharmaceuticals SA/NV; and Norbrook Laboratories.
Polaris Market Research has segmented the veterinary antibiotics market report on the basis of animal type, drug class, dosage form, and region:
By Animal Type Outlook (Revenue, USD Billion, 2020–2034)
Pigs
Cattle
Sheep & Goats
Poultry
Others
By Drug Class Outlook (Revenue, USD Billion, 2020–2034)
Tetracyclines
Penicillins
Sulfonamides
Macrolides
Trimethoprim
Lincosamides
Polymyxins
Aminoglycosides
Fluoroquinolones
Pleuromutilins
Other
By Dosage Form Outlook (Revenue, USD Billion, 2020–2034)
Oral Powders
Oral Solutions
Injections
Other
By Regional Outlook (Revenue, USD Billion, 2020–2034)
North America
Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America